ArticleDiscover oncology2025
Prognostic and immunotherapeutic response prediction in hepatocellular carcinoma: role of non-histone acetylation/deacetylation scoring.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- An Energy Model Based on Molecular Structure for Predicting Histone Modification Levels at lncRNA Promoter Regions in HepG2 Cells.International journal of molecular sciences · 2026Article
- Protein modification systems as cancer biomarkers and therapeutic targets.Precision clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundPost-translational modification is crucial, with acetylation and deacetylation enzymes playing important roles. Their roles in liver cancer, however, remain unclear.
methodsIn this study, a KAT + KDAC score was developed to assess the prognosis and response to immunotherapy in liver cancer patients. The association of HDAC1, HDAC2, and HDAC3 with patient prognosis was analyzed, and the PPI network was constructed. The correlation between the score and P53 mutation status, stage, and TNM staging was also investigated. Additionally, the response to chemotherapy was evaluated. The TIDE score was also assessed.
resultsOur analysis showed that HDAC1, HDAC2, and HDAC3 are highly associated with patient prognosis and are centrally located in the PPI network. Patients with high KAT + KDAC scores had a better prognosis, and the score correlated with P53 mutation status, stage, and TNM staging. Notably, patients with low KAT + KDAC scores demonstrate resistance to cisplatin and gemcitabine, and have a lower TIDE score. Moreover, the KAT + KDAC score accurately predicted patient response to immunotherapy.
conclusionThe KAT + KDAC modification pattern is critical in the initiation and progression of liver cancer. This score can be used to predict patient prognosis and immunotherapy response. Future studies are needed to further explore the underlying mechanisms and potential therapeutic applications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.